Dean Capital Investments Management LLC Sells 87 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Dean Capital Investments Management LLC lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.3% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,935 shares of the medical research company’s stock after selling 87 shares during the period. Dean Capital Investments Management LLC’s holdings in Thermo Fisher Scientific were worth $629,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. BlackRock Inc. raised its stake in Thermo Fisher Scientific by 1.4% during the 2nd quarter. BlackRock Inc. now owns 27,643,905 shares of the medical research company’s stock worth $8,118,461,000 after acquiring an additional 392,227 shares during the period. Mcrae Capital Management Inc. raised its stake in Thermo Fisher Scientific by 0.8% during the 3rd quarter. Mcrae Capital Management Inc. now owns 12,959 shares of the medical research company’s stock worth $3,775,000 after acquiring an additional 100 shares during the period. Lathrop Investment Management Corp raised its stake in Thermo Fisher Scientific by 0.4% during the 3rd quarter. Lathrop Investment Management Corp now owns 65,103 shares of the medical research company’s stock worth $18,963,000 after acquiring an additional 228 shares during the period. Marquette Asset Management LLC raised its stake in Thermo Fisher Scientific by 26.2% during the 3rd quarter. Marquette Asset Management LLC now owns 361 shares of the medical research company’s stock worth $105,000 after acquiring an additional 75 shares during the period. Finally, Virginia Retirement Systems ET AL raised its stake in Thermo Fisher Scientific by 532.5% during the 3rd quarter. Virginia Retirement Systems ET AL now owns 99,300 shares of the medical research company’s stock worth $28,923,000 after acquiring an additional 83,600 shares during the period. Hedge funds and other institutional investors own 87.89% of the company’s stock.

In other Thermo Fisher Scientific news, Director Jim P. Manzi sold 4,410 shares of the stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $332.32, for a total transaction of $1,465,531.20. Following the completion of the sale, the director now directly owns 21,632 shares of the company’s stock, valued at approximately $7,188,746.24. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 0.45% of the company’s stock.

Shares of TMO opened at $337.37 on Wednesday. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.91 and a quick ratio of 1.37. Thermo Fisher Scientific Inc. has a 1 year low of $246.67 and a 1 year high of $342.26. The company has a 50 day simple moving average of $330.41 and a two-hundred day simple moving average of $304.37. The firm has a market cap of $136.01 billion, a P/E ratio of 36.79, a price-to-earnings-growth ratio of 1.80 and a beta of 1.14.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, January 30th. The medical research company reported $3.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.54 by $0.01. Thermo Fisher Scientific had a net margin of 14.47% and a return on equity of 17.24%. The business had revenue of $6.83 billion during the quarter, compared to analyst estimates of $6.78 billion. During the same period last year, the firm posted $3.25 EPS. The company’s revenue was up 5.0% on a year-over-year basis. On average, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 13.61 earnings per share for the current year.

Thermo Fisher Scientific declared that its board has authorized a share repurchase plan on Friday, November 8th that allows the company to repurchase $2.50 million in shares. This repurchase authorization allows the medical research company to purchase shares of its stock through open market purchases. Shares repurchase plans are typically an indication that the company’s board believes its stock is undervalued.

A number of equities research analysts have commented on the stock. Cowen restated an “outperform” rating and set a $365.00 target price (up previously from $330.00) on shares of Thermo Fisher Scientific in a research note on Monday, January 6th. Citigroup raised their target price on shares of Thermo Fisher Scientific from $380.00 to $390.00 and gave the stock a “buy” rating in a research note on Friday, January 31st. Wells Fargo & Co decreased their target price on shares of Thermo Fisher Scientific from $350.00 to $345.00 and set an “equal weight” rating on the stock in a research note on Friday, January 31st. BTIG Research raised their target price on shares of Thermo Fisher Scientific from $342.00 to $372.00 and gave the stock an “in-line” rating in a research note on Friday, January 31st. Finally, Needham & Company LLC raised their target price on shares of Thermo Fisher Scientific from $331.00 to $341.00 and gave the stock a “buy” rating in a research note on Friday, January 31st. Four research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $335.20.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Featured Story: Profit Margin

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit